<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131040">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01795677</url>
  </required_header>
  <id_info>
    <org_study_id>JAK ALLO STUDY</org_study_id>
    <nct_id>NCT01795677</nct_id>
  </id_info>
  <brief_title>JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis</brief_title>
  <official_title>JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation  (HSCT)
      in patients with primary or secondary myelofibrosis : a prospective phase II
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation  (HSCT)
      in patients with primary or secondary myelofibrosis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>DFS</measure>
    <time_frame>24 months after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>DFS is defined as the probability to be alive and in remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HSCT</measure>
    <time_frame>24 months after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Rate of pre-graft splenectomy
Co-morbidity score defined by Sorror et al before RUXOLITINIB and after 4-month treatment just before transplantation
Post-graft haematological recovery: time to neutrophil engraftment, platelet and red blood cells transfusion independency
Acute GVHD grade II-IV  incidence
Chronic GVHD incidence
Overall survival, disease-free survival, non-relapse mortality
JAK2V617E allele burden and status at registration, 3, 7, 16 months after inclusion (centralization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PATIENTS CARACTERISTICS</measure>
    <time_frame>24 months after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients with and without donor
Rate of patients with donor who benefit from a transplantation:
Comorbidity score at registration and after 3 months
Platelet and red blood cells transfusion independency
Performance status evolution (ECOG)
General symptoms related to myelofibrosis  (questionnaire MF SAF)
Comparison of haematological response in patients with or without donor
Spleen size evolution
Comparison of quality of life in patients with and without  (questionnaire EORTC)
Comparison of overall survival in patients with and without donor
Incidence of severe infections
Cytokine measure at registration, 3, and 7 months after inclusion (centralization)
MPL JAK status (at registration, centralization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>RUXOLOTINIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolotinib : patient with donor HSCT  4 months later patients without donor: ruxolotinib alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolotinib</intervention_name>
    <description>Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor</description>
    <arm_group_label>RUXOLOTINIB</arm_group_label>
    <other_name>Kakavi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 69 years

          -  No comorbidity contraindicating the transplantation :

               -  Severe respiratory failure defined as dyspnea  grade III or more

               -  Severe cardiac failure defined as  EF &lt; or =  30%

               -  Severe renal failure defined as  creatinine clearance &lt; 30 ml/min or dialysis

               -  Dementia or non-ability to give informed consent for the protocol

               -  Major alteration of performance status defined as  ECOG &gt; 2

               -  Severe liver disease defined as a cirrhosis or bilirubin &gt; 2 x ULN, or AST/ALT &gt;
                  5 x ULN

          -  Primary or secondary myelofibrosis diagnosed according to WHO definition  (Tefferi,
             et al 2007)

          -  Palpable splenomegaly or splenomegaly measured by any imagery (maximum size&gt; 15 cm by
             ultrasound scan, Magnetic Resonance Imaging or computer tomography)

          -  Disease if intermediate or high risk according to published criteria and summarized
             as follows:

        At least one criterion among the following:

          -  Haemoglobin &lt; 100 gr/L (unrelated to medication toxicity)

          -  Leucocytes &lt; 4 G/L (unrelated to medication toxicity) or &gt; 25 G/L

          -  Poor prognosis cytogenetics :  complex karyotype, abnormalities of  chromosomes 5, 7
             or 17 , +8, 12p-, inv(3), 11q23

        Two criteria among the following criteria :

          -  General symptoms (weight lost &gt; 10% in less than 6 months, night swears, specific
             fever &gt; 37.5°C)

          -  Peripheral blastosis &gt; 1% observed at least twice

          -  Thrombocytopenia &lt; 100 G/L (unrelated to treatment toxicity)

        Exclusion Criteria:

          -  Myelofibrosis transformed into acute leukaemia with 20% blasts of more in blood or
             bone marrow

          -  Previous treatment with JAK2 inhibitor

          -  Thrombopenia &lt; 50 G/L

          -  Comorbidities contraindicating the transplantation

          -  Comorbidity score Sorror &gt; 3

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARIE ROBIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FIM/GOELAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie ROBIN, MD</last_name>
    <phone>33142499639</phone>
    <email>marie.robin@sls.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie ROLLAND NEYRET, CRA</last_name>
    <phone>33 476765096</phone>
    <email>VRolland-neyret@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ROBIN</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie ROLLAND NEYRET, Mrs</last_name>
      <phone>+3476765096</phone>
      <email>vrOlland-neyret@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Marie ROBIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://infodoc.inserm.fr/</url>
    <description>Goelams internet site</description>
  </link>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>December 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JAK2 inhibitor RUXOLITINIB</keyword>
  <keyword>Primary or secondary myelofibrosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
